EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Pharmacogenetic Markers on the Efficacy of Neoadjuvant FLOT Chemotherapy in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma

Denis Fedorinov iD, Vladimir Lyadov iD, Marina Lyadova, Sherzod Abdullaev iD, Anastasia Kachanova, Anna Filatova, Dmitriy Ivashchenko iD, Dmitry Sychev iD

International Journal of Molecular Sciences · 04.05.2026 · 27 (9) · 4114

DOI: 10.3390/ijms27094114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.05.2026. Verfasst von Denis Fedorinov und 7 weiteren Autor:innen. Beteiligte Einrichtung: Federal State Budgetary Research Institution «Russian Research Center of Surgery Named After Academician B.V. Petrovsky», Moscow 119991, Russia. Hauptthemen laut MEDLINE: Adenocarcinoma, Stomach Neoplasms, Esophagogastric Junction, Esophageal Neoplasms. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the adoption of neoadjuvant FLOT chemotherapy as standard treatment for locally advanced gastric and gastroesophageal junction cancer, many patients fail to achieve meaningful pathological response, limiting efficacy. The aim of this study was to evaluate the impact of pharmacogenetic markers on pathological response in Russian patients receiving neoadjuvant FLOT. Thirty patients with locally advanced gastric or gastroesophageal junction adenocarcinoma received neoadjuvant FLOT followed by surgery. Polymorphisms in CYP3A5 (rs776746), CYP2C8 (rs10509681, rs11572080, rs1058930), ERCC1 (rs11615), and GSTP1 (rs1695) were analyzed. Favorable pathological response (TRG0-2) was observed in 23.3% of patients, including 3.3% complete responses. Most patients (76.7%) had minimal or no regression (TRG3-5). Clinical variables were not associated with response. ERCC1 (rs11615) showed a significant association: patients with the Wt/Wt genotype had higher odds of achieving TRG0-2 (OR = 8.889; p = 0.033; 95% CI: 1.294–61.058). No associations were found for CYP3A5, CYP2C8, or GSTP1. Median PFS was 18.21 months in TRG3-5, while not reached in TRG0-2 (p = 0.108). No significant PFS differences by ERCC1 genotype were observed (p = 0.525). ERCC1 (rs11615) may serve as a potential pharmacogenetic marker of response to FLOT, supporting further research in personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaStomach NeoplasmsEsophagogastric JunctionEsophageal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleNeoadjuvant TherapyMiddle AgedAgedDNA-Binding ProteinsEndonucleasesPolymorphism, Single NucleotideTreatment OutcomeBiomarkers, TumorGlutathione S-Transferase piPharmacogeneticsAdult

Stichwörter der Autor:innen

ERCC1cancergenegeneticsgenomegenotypepharmacogeneticspharmacogenomics

Substanzen

ERCC1 protein, humanDNA-Binding ProteinsEndonucleasesBiomarkers, TumorGlutathione S-Transferase piGSTP1 protein, human

Autor:innen und Institutionen

  • Federal State Budgetary Research Institution «Russian Research Center of Surgery Named After Academician B.V. Petrovsky», Moscow 119991, Russia.
  • Moscow Multidisciplinary Clinical Center "Kommunarka", Moscow 108814, Russia.
  • Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation, Moscow 125993, Ru…
  • Moscow State Budgetary Healthcare Institution "Oncological Center No. 1 of Moscow City Hospital Named After S.S. Yudin, Moscow Healthcare Department", Moscow 115446, Russia.
  • Department of Oncology, Novokuznetsk State Institute of Postgraduate Medical Education-Branch of Russian Medical Academy of Continuous Professional Education, Novokuznetsk 654005, Russia.
  • E.M. Tareev Clinic of Rheumatology, Nephrology, and Occupational Pathology. I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia.

ORCID-Profile: Denis Fedorinov, Vladimir Lyadov, Sherzod Abdullaev, Dmitriy Ivashchenko, Dmitry Sychev

Förderung

  • Ministry of Science and Higher Education of the Russian Federation

Zitieren

APA

Fedorinov, D., Lyadov, V., Lyadova, M., Abdullaev, S., Kachanova, A., Filatova, A., Ivashchenko, D., & Sychev, D. (2026). Impact of Pharmacogenetic Markers on the Efficacy of Neoadjuvant FLOT Chemotherapy in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma. International Journal of Molecular Sciences, 27(9), 4114. https://doi.org/10.3390/ijms27094114

Vancouver

Fedorinov D, Lyadov V, Lyadova M, Abdullaev S, Kachanova A, Filatova A, et al. Impact of Pharmacogenetic Markers on the Efficacy of Neoadjuvant FLOT Chemotherapy in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma. International Journal of Molecular Sciences. 2026;27(9):4114. doi:10.3390/ijms27094114

BibTeX
@article{Fedorinov2026,
  author = {Fedorinov, Denis and Lyadov, Vladimir and Lyadova, Marina and Abdullaev, Sherzod and Kachanova, Anastasia and Filatova, Anna and Ivashchenko, Dmitriy and Sychev, Dmitry},
  title = {Impact of Pharmacogenetic Markers on the Efficacy of Neoadjuvant FLOT Chemotherapy in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {9},
  pages = {4114},
  doi = {10.3390/ijms27094114}
}
Kostenlos starten →